Yaniv Erlich on building a scalable platform to discover next-gen RNA therapeutics.
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Yaniv Erlich on building a scalable platform to discover next-gen RNA therapeutics.
-
ナレーター：
-
著者：
このコンテンツについて
Prof. Yaniv Erlich received his bachelor’s degree from Tel-Aviv University, Israel in 2006 and a PhD from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory in 2010. Yaniv Erlich was an Associate Professor of Computer Science at Columbia University and was a PI at the Whitehead Institute, MIT.
His research interests are computational human genetics. Yaniv has been an advisor for multiple companies in the area of genomics and bioinformatics. He authored over 40 peer-reviewed scientific studies, including multiple papers in Science, Nature Genetics, and Nature Methods. He holds five patents and has experience in both B2C and B2B in the area of genomics.
Prof. Yaniv Erlich was the CSO of MyHeritage and currently he is the CEO of Eleven Therapeutics, a company that he co-founded in 2020. Eleven Therapeutics is a biotech company focused on development of groundbreaking RNA therapeutics.